(Q33261650)

24 July 2017

title

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence (English)

1 reference

24 July 2017

Kim A Papp

1

0 references

author name string

Darryl Toth

series ordinal

2

1 reference

24 July 2017

Les Rosoph

series ordinal

3

1 reference

24 July 2017

publication date

26 October 2006

1 reference

24 July 2017

1 reference

24 July 2017

volume

6

1 reference

24 July 2017

page(s)

9

1 reference

Efalizumab: a review of events reported during clinical trials and side effects

24 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Relapse, rebound, and psoriasis adverse events: an advisory group report.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Generalized pustular psoriasis following withdrawal of efalizumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Treatment of psoriasis. Part 2. Systemic therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Psoriasis causes as much disability as other major medical diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

Generalized pustular psoriasis. A report on thirteen patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

The prevalence of psoriasis in African Americans: results from a population-based study.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-5945-6-9

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-5945-6-9

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1636659

LIFE-THREATENING PSORIASIS RELAPSE ON WITHDRAWAL OF CYCLOSPORIN

31 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-5945-6-9

Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy

21 January 2018

1 reference

12 December 2020

The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison

1 reference

12 December 2020

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

12 December 2020

Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice

1 reference

12 December 2020

Efficacy and safety of treatment modalities for psoriasis

1 reference

12 December 2020

Definitions of Measures of Effect Duration for Psoriasis Treatments

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-5945-6-9

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference

24 July 2017

1 reference